THERAPEUTIC EPIGENETIC ENHANCEMENT OF THE INNATE IMMUNITY TO EFFECTIVELY COMBAT ANTIMICROBIAL RESISTANCE [IN-ARMOR]

Informazioni relative al progetto

IN-ARMOR

ID dell’accordo di sovvenzione: 101080889

DOI

10.3030/101080889

Data della firma CE 15 Marzo 2023

Data di avvio 1 Maggio 2023

Data di completamento 30 Aprile 2027

Finanziato da

• Health

Costo totale

€ 5 998 972,50

Contributo UE

€ 5 998 972,25

Coordinato da

HASKOLI ISLANDS
Iceland

CORDIS fornisce collegamenti ai risultati finali pubblici e alle pubblicazioni dei progetti ORIZZONTE.

I link ai risultati e alle pubblicazioni dei progetti del 7° PQ, così come i link ad alcuni tipi di risultati specifici come dataset e software, sono recuperati dinamicamente da .OpenAIRE .

Risultati finali

Documents, reports (4)

Plan for Dissemination of Results (PDR), with Project Communication Plan (PCP)

Document containing the definition of the dissemination of results and communication plan and tools to be used during the life of the project. All possible dissemination routes for the obtained results will be identified and used during the whole course of the project.

Review of costs related to GI diseases. Elaboration of a scientific health-economics report with results from CEA based on current available studies on GI diseases.

The Document will consider data on the resources used in different treatment strategies of immunotherapies for GI diseases and the unit cost or price per resource and the main effects in terms of health gain. The analysis will capture the variability in the use and costs of the resources between multi-clinical units and in relation to patient status.

Health Technology Assessment structure definition.

Document presenting the basic structure of the HTA report, which will be continuously fulfilled as results of project are produced  and the information for these  parts of the HTA will be known: problem and new therapy description,  clinical effectiveness and safety,  costs and economic evaluation,  ethical aspects,  organisational aspects,  patients and social aspects. HTA report will present the projects outcomes and its effects on society, that may occur when a therapy is introduced, extended, or modified, with emphasis on the impacts that are direct but also unintended or indirect.

Policy Briefing I

On-page policy briefing to be shared with policy makers and their DGs. The document will list the achievements and results to date, pathways to impact and next steps to be taken.

Websites, patent fillings, videos etc. (1)

In-Armor public website and social channels

Document describing In-Armor webpage prepared in the first month of the project.

Pubblicazioni

Peer reviewed articles (3)

Impact of HDAC inhibitors on macrophage polarization to enhance innate immunity against infections

Autori: Mohammad Faizan Bhat, Sonja Srdanović, Lotta-Riina Sundberg, Helga Kristín Einarsdóttir, Varpu Marjomäki, Frank J. Dekker
Pubblicato in: Drug Discovery Today, Numero 29, 2024, ISSN 1359-6446
Editore: Elsevier BV
DOI: 10.1016/j.drudis.2024.104193

Histone Deacetylase 3‐Directed PROTACs Have Anti‐inflammatory Potential by Blocking Polarization of M0‐like into M1‐like Macrophages

Autori: Chunlong Zhao, Shipeng Chen, Deng Chen, Clàudia Río‐Bergé, Jianqiu Zhang, Petra E. Van Der Wouden, Toos Daemen, Frank J. Dekker
Pubblicato in: Angewandte Chemie International Edition, Numero 62, 2023, ISSN 1433-7851
Editore: Wiley
DOI: 10.1002/anie.202310059

Host-directed therapies modulating innate immunity against infection in hematologic malignancies

Autori: Qiong Wang, Kristján Hermannsson, Egill Másson, Peter Bergman, Guðmundur Hrafn Guðmundsson
Pubblicato in: Blood Reviews, 2024, ISSN 0268-960X
Editore: Elsevier BV
DOI: 10.1016/j.blre.2024.101255